Search Within

Allison Betof Warner

Formats
  1. Meeting Abstract (35)
  2. Journal Article (32)
  3. Review (6)
  4. Correspondence (1)
  5. Editorial (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (77)
  2. Hematologic Malignancies, Division of (77)
  3. Melanoma and Immunotherapeutics Service (77)
  4. Solid Tumor Oncology Division (77)
  5. Weinberg Fellows (77)
  6. Melanoma Disease Management Team (38)

More Groups

People
  1. Jedd Wolchok (29)
  2. Michael Postow (29)
  3. Alexander Shoushtari (25)
  4. Margaret Callahan (19)
  5. Katherine Panageas (18)
  6. Paul Chapman (18)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (10)
  4. 2022 (15)
  5. 2021 (17)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Journal for ImmunoTherapy of Cancer (8)
  3. Cancer Research (6)
  4. Clinical Cancer Research (5)
  5. Annals of Oncology (4)
  6. International Journal of Radiation Oncology, Biology, Physics (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (19)
  2. American Association for Cancer Research (11)
  3. Biomed Central Ltd (9)
  4. Elsevier Inc. (9)
  5. Oxford University Press (5)
  6. Wiley Blackwell (4)

More Publishers

Results (77)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune suppressive mechanism of corticosteroids used for immune-related adverse events
    Meeting Abstract

    Maeda, Y.; Tokunaga, A.; Sugiyama, D.; Warner, A. B.; Wolchok, J. D.; Nishikawa, H.
    Cancer Science (2018)

    Fulltext@MSK | Save
  • Bigger is not always better: Tumor size and prognosis in advanced melanoma
    Journal Article

    Warner, A. B.; Postow, M. A.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Combination controversies: Checkpoint inhibition alone or in combination for the treatment of melanoma?
    Journal Article

    Warner, A. B.; Postow, M. A.
    Oncology (Norwalk) (2018)

    Fulltext@MSK | Save
  • The brim of uncertainty in adjuvant treatment of melanoma
    Journal Article

    Warner, A. B.; Postow, M. A.
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
    Journal Article

    Rosner, S.; Kwong, E.; Shoushtari, A. N.; Friedman, C. F.; Betof, A. S.; Brady, M. S.; Coit, D. G.; Callahan, M. K.; Wolchok, J. D.; Chapman, P. B.; more...
    Cancer Medicine (2018)

    Fulltext@MSK | Save
  • Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Journal Article

    Pollack, M. H.; Betof, A.; Dearden, H.; Rapazzo, K.; Valentine, I.; Brohl, A. S.; Ancell, K. K.; Long, G. V.; Menzies, A. M.; Eroglu, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • End-of-life care for patients with potentially resectable pancreatic cancer who received radiation therapy
    Meeting Abstract

    Yerramilli, D.; Betof, A.; Drapek, L. C.; Wo, J. Y.; Hong, T. S.; Nipp, R.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save